DAPT Score
Weighs the ischemic benefit against the bleeding harm of extending dual antiplatelet therapy beyond 12 months after PCI; apply at 12 months post-PCI only in patients who are event-free and tolerating DAPT.
Weighs the ischemic benefit against the bleeding harm of extending dual antiplatelet therapy beyond 12 months after PCI; apply at 12 months post-PCI only in patients who are event-free and tolerating DAPT.